Reuse of Nevirapine in Pregnancies to Prevent HIV Transmission
Author Information
Author(s): Walter Jan, Louise Kuhn, Chipepo Kankasa, Katherine Semrau, Moses Sinkala, Thea Donald M, Grace M Aldrovandi
Primary Institution: Childrens Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA
Hypothesis
Does the reuse of single-dose nevirapine (SDNVP) in subsequent pregnancies affect its efficacy in preventing mother-to-child HIV transmission?
Conclusion
The efficacy of SDNVP may not be diminished when reused in subsequent pregnancies.
Supporting Evidence
- Transmission risks did not differ significantly between SDNVP-exposed and unexposed women.
- Among women with two consecutive pregnancies, transmission risks were similar for both deliveries.
- Women who reused SDNVP did not experience increased transmission rates despite disease progression.
Takeaway
Giving the same medicine to moms during different pregnancies to stop babies from getting HIV seems to work just as well each time.
Methodology
The study compared perinatal HIV transmission risks between women who had previously received SDNVP and those who had not, using logistic regression to adjust for confounders.
Limitations
The study's small size limits the definitiveness of the findings.
Participant Demographics
Women enrolled were HIV-infected multiparous mothers in Lusaka, Zambia.
Statistical Information
P-Value
0.11
Confidence Interval
95% CI: 0.2 to 2.0
Statistical Significance
p = 0.11
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website